The current financial score of Myriad Genetics Inc is 6.84. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 190.70M, representing a year-over-year decrease of 10.51%, while its net profit experienced a year-over-year decrease of 86.93%.
The current valuation score of Myriad Genetics Inc is 7.97. Its current P/E ratio is -0.96, which is -30.92% below the recent high of -0.66 and -2142.88% above the recent low of -21.52.
The current earnings forecast score of Myriad Genetics Inc is 5.40. The average price target is 3.37, with a high of 5.00 and a low of 2.00.
The current price momentum score of Myriad Genetics Inc is 5.74. Currently, the stock price is trading between the resistance level at 4.62 and the support level at 3.29, making it suitable for range-bound swing trading.
The current institutional shareholding score of Myriad Genetics Inc is 10.00. The latest institutional shareholding proportion is 109.00%, representing a quarter-over-quarter increase of 9.24%.
The current risk assessment score of Myriad Genetics Inc is 3.06. The company's beta value is 1.81. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.